tiprankstipranks
Trending News
More News >
Monash IVF Group Ltd (AU:MVF)
:MVF
Advertisement

Monash IVF Group Ltd (MVF) AI Stock Analysis

Compare
41 Followers

Top Page

AU

Monash IVF Group Ltd

(Sydney:MVF)

Rating:55Neutral
Price Target:
AU$1.00
▲(31.58%Upside)
The overall score is primarily influenced by the company's mixed financial performance, with strong cash flow but operational losses. Technical analysis shows short-term positive momentum but longer-term weakness. Valuation is challenged by negative earnings, although the high dividend yield provides some appeal.

Monash IVF Group Ltd (MVF) vs. iShares MSCI Australia ETF (EWA)

Monash IVF Group Ltd Business Overview & Revenue Model

Company DescriptionMonash IVF Group Limited provides assisted reproductive and specialist women imaging services in Australia and Malaysia. The company offers diagnostic obstetric, gynecological ultrasound, and fertility treatment services. It also provides tertiary level prenatal diagnostic and IVF treatment services. The company was incorporated in 2014 and is based in Richmond, Australia.
How the Company Makes MoneyMonash IVF Group Ltd generates revenue primarily through its fertility treatment services, which include IVF cycles, genetic testing, and other assisted reproductive technologies (ART). The company also earns income from its specialist women's imaging services, which provide diagnostic imaging and ultrasound services focused on women's health. Key revenue streams include patient fees for fertility treatments and diagnostic services. Strategic partnerships with healthcare providers and research institutions further support its business model by enhancing service offerings and expanding market reach. Additionally, Monash IVF Group benefits from a reputation for clinical excellence and innovation, which attracts clients and supports sustained demand for its services.

Monash IVF Group Ltd Financial Statement Overview

Summary
Monash IVF Group Ltd shows mixed financial health. Despite robust revenue growth and strong cash flow generation, the company faces profitability challenges with recent operational losses. Its balance sheet shows moderate leverage, which requires monitoring. The company needs to focus on improving operational efficiencies to turn revenue growth into sustainable profits.
Income Statement
45
Neutral
The income statement shows cause for concern with a negative EBIT and net income for the most recent year, indicating operational losses. Revenue growth rate was strong at 19.4% compared to the previous year, but this has not translated into profit growth due to higher costs. Gross profit margin stands at 33.5%, down from previous years, indicating increased cost pressures.
Balance Sheet
60
Neutral
The balance sheet reveals a stable equity base with stockholders' equity at 47.6% of total assets. However, the debt-to-equity ratio is relatively high at 0.56, suggesting moderate leverage. Return on equity has turned negative due to the net loss, which is a risk factor.
Cash Flow
70
Positive
Cash flow is a bright spot with a strong operating cash flow to net income ratio, indicating good cash generation relative to net income. Free cash flow grew significantly by 203.6% year-over-year, highlighting effective capital expenditure management. However, the net loss casts a shadow on future cash flow sustainability.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue254.96M213.59M192.29M183.60M145.42M
Gross Profit85.50M63.41M57.22M57.66M38.37M
EBITDA13.03M48.49M45.69M51.21M32.84M
Net Income-6.53M21.84M18.41M25.15M11.73M
Balance Sheet
Total Assets508.47M421.89M387.10M356.17M354.22M
Cash, Cash Equivalents and Short-Term Investments11.33M8.01M7.87M8.76M15.07M
Total Debt135.37M100.04M77.23M45.99M57.57M
Total Liabilities261.81M146.82M117.20M87.73M102.10M
Stockholders Equity241.91M273.20M267.92M266.19M249.81M
Cash Flow
Free Cash Flow30.85M10.16M19.51M33.30M19.04M
Operating Cash Flow52.52M37.95M31.28M43.25M26.54M
Investing Cash Flow-38.80M-40.51M-15.16M-11.21M-9.26M
Financing Cash Flow-10.39M2.68M-17.02M-38.35M-6.46M

Monash IVF Group Ltd Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.76
Price Trends
50DMA
0.73
Positive
100DMA
0.87
Negative
200DMA
1.02
Negative
Market Momentum
MACD
0.01
Negative
RSI
57.59
Neutral
STOCH
65.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MVF, the sentiment is Positive. The current price of 0.76 is above the 20-day moving average (MA) of 0.72, above the 50-day MA of 0.73, and below the 200-day MA of 1.02, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 57.59 is Neutral, neither overbought nor oversold. The STOCH value of 65.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:MVF.

Monash IVF Group Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUSHL
73
Outperform
AU$13.48B24.006.86%3.22%10.15%6.20%
AUACL
66
Neutral
AU$559.72M18.5218.39%2.46%7.80%99.87%
AUMVF
55
Neutral
AU$296.12M-0.87%6.84%14.24%-109.59%
AUIDX
53
Neutral
AU$990.66M109.471.14%1.88%7.83%
46
Neutral
C$195.87M-3.27-23.14%2.64%20.75%-0.36%
AUHLS
46
Neutral
AU$566.38M-4.46%-7.82%98.08%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:MVF
Monash IVF Group Ltd
0.76
-0.47
-38.21%
AU:HLS
Healius Limited
0.78
-0.30
-27.71%
AU:SHL
Sonic Healthcare Limited
27.61
2.03
7.94%
AU:IDX
Integral Diagnostics Ltd.
2.66
0.22
9.02%
AU:ACL
Australian Clinical Labs Ltd
2.85
0.49
20.76%

Monash IVF Group Ltd Corporate Events

Monash IVF Group to Release Restricted Shares from Escrow
Jul 16, 2025

Monash IVF Group Ltd announced the release of 965,753 fully paid ordinary shares from voluntary escrow, effective 30 July 2025. This release does not affect the company’s issued capital, as 10,000,258 shares remain under escrow, indicating a strategic move that maintains the company’s market stability while potentially enhancing liquidity.

The most recent analyst rating on (AU:MVF) stock is a Buy with a A$1.55 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.

Monash IVF Group Names Interim CFO Amid Leadership Transition
Jul 16, 2025

Monash IVF Group Limited has appointed Andrew MacLachlan as the Interim Chief Financial Officer, effective immediately. This strategic move aims to bolster the company’s financial leadership while the search for a permanent CEO continues, ensuring stability and expertise in its financial operations during this transitional period.

The most recent analyst rating on (AU:MVF) stock is a Buy with a A$1.55 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.

Monash IVF Addresses Late Lodgement of CEO Resignation Notice
Jun 24, 2025

Monash IVF Group Limited announced the late lodgement of an Appendix 3Z following the resignation of Michael Knaap as Chief Executive Officer and Managing Director. The company acknowledged the oversight and emphasized its commitment to compliance with ASX disclosure obligations, stating that it will implement further measures to prevent future occurrences.

The most recent analyst rating on (AU:MVF) stock is a Buy with a A$1.55 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.

Challenger Limited Ceases Substantial Holding in Monash IVF Group
Jun 12, 2025

Challenger Limited, along with its associated entities, has announced that it has ceased to be a substantial holder in Monash IVF Group Limited. This change in holding could potentially impact Monash IVF Group’s shareholder structure and influence its market dynamics, as Challenger Limited’s exit may alter investor perceptions and stakeholder interests.

The most recent analyst rating on (AU:MVF) stock is a Buy with a A$1.55 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.

Monash IVF Group Announces CEO Resignation and Interim Leadership
Jun 12, 2025

Monash IVF Group Ltd announced the resignation of CEO and Managing Director Michael Knaap, who has been with the company since 2019, leading it through significant growth and transformation. Malik Jainudeen, the current Chief Financial Officer and Company Secretary, has been appointed as Acting CEO, bringing over a decade of experience with the company and a strong background in financial and healthcare sectors.

The most recent analyst rating on (AU:MVF) stock is a Buy with a A$1.55 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.

Monash IVF Addresses Embryo Transfer Incident with Enhanced Safeguards
Jun 10, 2025

Monash IVF Group Limited announced an incident at its Clayton laboratory where an embryo was incorrectly transferred, prompting an internal investigation and an expanded independent review. The company is implementing additional verification processes to prevent future occurrences and has informed relevant regulators and insurers, while maintaining its profit guidance.

The most recent analyst rating on (AU:MVF) stock is a Buy with a A$1.55 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.

Monash IVF Group Revises FY2025 Profit Guidance Amid Challenging Market Conditions
May 19, 2025

Monash IVF Group Limited has revised its profit guidance for the fiscal year ending June 2025, now expecting an underlying NPAT of approximately $27.5 million, down from the previously anticipated $30.0 million to $31.0 million. This adjustment is due to softer market and operating conditions experienced in March and April 2025, although some recovery was noted in May. The company is also monitoring potential impacts from a recent incident in Brisbane, which could affect patient registrations and other operational metrics.

The most recent analyst rating on (AU:MVF) stock is a Buy with a A$1.55 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.

Monash IVF Addresses ASX Inquiry on Isolated Incident
Apr 23, 2025

Monash IVF Group Ltd responded to an ASX inquiry regarding an incident of human error, which they consider isolated and not materially affecting their financial performance for FY2025. The company has initiated an independent investigation to address the incident responsibly, and while the announcement was marked as market sensitive due to its financial commentary, MVF maintains that the information was not initially disclosed as it was not deemed obligatory under listing rules.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 15, 2025